Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 91.37% is in line with its 5-year average of 84.32%, near the high end of its 5-year range (-3156.51%–136.26%).
16.72% above its 12-month average of 78.28%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.14%.
GROSS MARGIN
91.37%
GROSS MARGIN AVG TTM
78.28%
GROSS MARGIN AVG 3Y
85.81%
GROSS MARGIN AVG 5Y
84.32%
GROSS MARGIN AVG 10Y
29.01%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+16.72%
CURRENT VS 3Y AVG
+6.48%
CURRENT VS 5Y AVG
+8.36%
CURRENT VS 10Y AVG
+214.98%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+121.74%
vs the sector median at left
Market Cap
$24.44M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$23.38M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
99.50%
5Y Avg
86.48%
Market Cap
$23.06M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$25.22M
Gross Margin
0.00%
TTM Avg
49.92%
3Y Avg
18.04%
5Y Avg
44.48%
Market Cap
$22.25M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$22.00M
Gross Margin
63.95%
TTM Avg
66.50%
3Y Avg
67.57%
5Y Avg
61.13%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kyntra Bio, Inc. (KYNB) | $24.13M | 91.37% | 78.28% | 85.81% | 84.32% |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.44M | 0.00% | 0.00% | 0.00% | 0.00% |
| InspireMD, Inc. (NSPR)vs › | $24.60M | 29.50% | 25.49% | 25.43% | 20.30% |
| TherapeuticsMD, Inc. (TXMD)vs › | $23.38M | 100.00% | 100.00% | 99.50% | 86.48% |
| Rein Therapeutics Inc. (RNTX)vs › | $23.06M | 0.00% | 0.00% | 0.00% | 0.00% |
| ABVC BioPharma, Inc. (ABVC)vs › | $25.22M | 0.00% | 49.92% | 18.04% | 44.48% |
| LeonaBio, Inc. (LONA)vs › | $22.68M | 0.00% | 0.00% | 0.00% | 0.00% |
| Modular Medical, Inc. (MODD)vs › | $22.25M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.00M | 63.95% | 66.50% | 67.57% | 61.13% |
| Tevogen Bio Holdings Inc. (TVGN)vs › | $27.03M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
91.4%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.14% |
| 2026-03-31 | -9.84% |
| 2025-12-31 | 136.26% |
| 2025-09-30 | 87.55% |
| 2025-06-30 | 77.30% |
| 2025-03-31 | 78.86% |
| 2024-12-31 | 83.23% |
| 2024-09-30 | 88.57% |
| 2024-06-30 | -3156.51% |
| 2024-03-31 | -128.01% |
| 2023-12-31 | 80.08% |
| 2023-09-30 | 89.43% |
| 2023-06-30 | 87.12% |
| 2023-03-31 | 90.35% |
| 2022-12-31 | 85.67% |
| 2022-09-30 | 72.62% |
| 2022-06-30 | 77.16% |
| 2022-03-31 | -53.31% |
| 2021-12-31 | 65.50% |
| 2021-09-30 | 49.26% |
| 2021-06-30 | -415.70% |
| 2021-03-31 | -103.17% |
| 2020-12-31 | 95.98% |
| 2020-09-30 | 94.99% |
| 2020-06-30 | 92.83% |
| 2020-03-31 | 96.02% |
| 2019-12-31 | 88.65% |
| 2019-09-30 | 99.27% |
| 2019-06-30 | 72.85% |
| 2019-03-31 | -111.61% |
| 2018-12-31 | 34.95% |
| 2018-09-30 | -94.45% |
| 2018-06-30 | -18.62% |
| 2018-03-31 | -78.46% |
| 2017-12-31 | -23.43% |
| 2017-09-30 | -84.57% |
| 2017-06-30 | -62.02% |
| 2017-03-31 | -73.78% |
| 2016-12-31 | -58.58% |
| 2016-09-30 | -34.74% |
| 2016-06-30 | 41.32% |
| 2016-03-31 | -54.34% |
| 2015-12-31 | -145.17% |
| 2015-09-30 | -166.51% |
| 2015-06-30 | 57.23% |
| 2015-03-31 | -210.09% |
| 2014-12-31 | -218.27% |
| 2014-09-30 | -197.30% |
| 2014-06-30 | 63.02% |
| 2014-03-31 | -43.49% |
| 2013-12-31 | -137.56% |
| 2013-09-30 | 67.46% |
| 2013-06-30 | -14.83% |
| 2013-03-31 | -431.16% |
